Macdougall, Iain C.Iain C.MacdougallMeadowcroft, Amy M.Amy M.MeadowcroftBlackorby, AllisonAllisonBlackorbyCizman, BorutBorutCizmanCobitz, Alexander R.Alexander R.CobitzGodoy, SergioSergioGodoyJha, VivekanandVivekanandJhaJohansen, Kirsten L.Kirsten L.JohansenMcMahon, GearoidGearoidMcMahonObrador, GregorioGregorioObradorWong, Muh GeotMuh GeotWongSingh, Ajay K.Ajay K.Singh2023-07-112023-07-112023Macdougall, I. C., Meadowcroft, A. M., Blackorby, A., Cizman, B., Cobitz, A. R., Godoy, S., Jha, V., Johansen, K. L., McMahon, G., Obrador, G. T., Wong, M. G., & Singh, A. K. (2023). Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). In American Journal of Nephrology (Vol. 54, Issues 1–2, pp. 1–13). S. Karger AG. https://doi.org/10.1159/000528696https://scripta.up.edu.mx/handle/123456789/360810.1159/000528696Introduction: Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) affects 10-15% of the chronic dialysis population. We explored baseline characteristics and predictors of ESA hyporesponsiveness in a global randomized cardiovascular outcomes study comparing an investigational hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), daprodustat, with conventional ESA treatment. Methods: ASCEND-D (NCT02879305) recruited 2,964 chronic dialysis patients receiving ESA treatment (standardized to weekly intravenous [IV] epoetin) who were iron replete at baseline. The primary ESA hyporesponsiveness definition was an ESA Resistance Index (ERI, ESA units/kg/week/hemoglobin g/L) ≥2 or IV standardized ESA dose ≥450 units/kg/week. Predictors of ESA hyporesponsiveness were determined using a multivariable regression model. Alternative hyporesponder definitions were explored. The Author(s). Published by S. Karger AG, Basel.enAnemiaClinical trialDialysisErythropoiesis-stimulating agentHemoglobinResource Types::text::journal::journal article